Anti lc3b 2775 s

The following commercially available antibodies were used: anti-Actin (Mab1501R, Millipore), anti-HSP60 (SC-1054, Santa Cruz Biotech), anti-LAMP1 (1D4B, Developmental Studies Hybridoma Bank), anti-P62 (PM045, MBL), anti-LC3B (2775 s, Cell Signaling), anti-c-Myc (C3956, Sigma), anti-Ubiquitin (P4D1, Cell Signaling), anti-PINK1 (75488, Abcam), anti-TBC1D15 (121396, Abcam), anti-PARKIN (15954, Abcam), and anti-MUL1 (HPA017681, Sigma).
For Western analysis, densitometry was done using ImageJ. The intensity of the ubiquitin signal was normalized to that of HSP60, and the average of three separate experiments was taken.

Trypan blue solution (T8154), sodium orthovanadate (Na₃VO₄) (S6508), 3-methyladenine (3-MA; M9281), chloroquine diphosphate (CQ; C6628), and phosphatase inhibitor cocktails 2 and 3 (P5726, P0044), NP40 (I8896), okadaic acid (O7885), aprotinin (A1153), pepstatin A (P5318), leupeptin (L2884), and phenylmethanesulfonyl fluoride (PMSF) (93482) were purchased from Sigma-Aldrich, and protease inhibitor cocktail (11 836 153 001) from Roche Diagnostics. The siRNAs against ATG7 (sc-41447), and Control siRNA-A (siCon) (sc-37007) were purchased from Santa Cruz Biotechnology. The ATG7 siRNAs are a pool of 3 target-specific 19–25 nt siRNAs.
Primary antibodies: anti-EGFR (2232), anti-ATG7 (8558), anti-LC3B (2775S), and anti-HA (3724) were purchased from Cell Signaling Technology, anti-TSSC4 (sc-136945) from Santa Cruz Biotechnology, and anti-ACTB/actin beta from Sigma-Aldrich (A3853). Secondary antibodies: goat anti-rabbit IgG (H⁺L)-HRP conjugate (170–6515) and goat anti-mouse IgG (H⁺L)-HRP conjugate (170–6516) were obtained from Bio-Rad Laboratories.